性结肠炎患者在阿达利穆马布治疗期间肠道微生物组合的动态变化:对治疗反应预测和治疗点的影响
Han Na Oh1,2, Seung Yong Shin3, Jong-Hwa Kim4
1Department of Systems Biotechnology, Chung-Ang University, Anseong, 17546, Republic of Korea.
在性结肠炎 (UC) 患者的肠道微生物组长度分析中,接受阿达利穆马布 (ADA) 治疗的患者显示出明显的微生物转移. 转发者显示微生物组不相似性减少和特定的细菌变化,有助于预测治疗反应.
科学领域:
- 胃肠病学 胃肠病学
- 微生物组研究 微生物组研究
- 免疫学 免疫学 免疫学
背景情况:
- 在治疗性结肠炎 (UC) 的抗瘤缩因子-α (抗TNF-α) 治疗期间对纵向肠道微生物群动态的理解有限.
- 以前的研究集中在治疗后的变化,而不是治疗期间的动态变化.
研究的目的:
- 为了研究UC患者的肠道微生物组的时间变化,这些患者正在接受阿达利姆巴 (ADA) 的抗TNF-α治疗.
- 识别与治疗反应和临床缓解相关的微生物特征.
主要方法:
- 在ADA治疗期间,在UC患者的肠道微生物群的纵向采样.
- 对安普利康序列变异 (ASV) 的分析,以评估微生物群体的组成和不相似性.
- 接收器操作特征 (ROC) 曲线分析,以根据治疗前的微生物概况预测临床缓解.
主要成果:
- 与健康对照组相比,UC患者表现出不同的微生物群落,受疾病严重程度的影响.
- 随着时间的推移,Adalimumab治疗导致了可识别的ASV差异.
- 肠道微生物组不相似性的显著减少仅在实现临床缓解的患者中观察到.
- 发送者显示,伯克霍尔德里亚-卡巴勒罗尼亚-帕拉伯克霍尔德里亚和葡萄球菌的相对丰度下降,比菲多细菌和多雷亚的增加.
- 治疗前的微生物形状预测了第8周的临床缓解,具有高灵敏度 (72.4%) 和特异性 (84.3%) (AUC=0.851).
结论:
- 在UC患者的阿达利穆马布治疗期间,肠道微生物群的组成会有动态变化.
- 这些微生物变化与治疗反应和临床结果相关.
- 鉴定的微生物转移为预测ADA反应和UC的新疗法目标提供了潜在的生物标志物.
更多相关视频
05:41Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
